151 related articles for article (PubMed ID: 35659904)
1. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials.
Savarino SJ; Bonaparte M; Wang H; Dayan GH; Forrat R; Zhu M; Hodge S; Ataman-Önal Y; DiazGranados CA
Lancet Microbe; 2022 Jun; 3(6):e427-e434. PubMed ID: 35659904
[TBL] [Abstract][Full Text] [Related]
2. Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.
DiazGranados CA; Bonaparte M; Wang H; Zhu M; Lustig Y; Schwartz E; Forrat R; Dayan GH; Hodge S; Ataman-Önal Y; Savarino SJ
Lancet Infect Dis; 2021 Apr; 21(4):529-536. PubMed ID: 33212068
[TBL] [Abstract][Full Text] [Related]
3. Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
Liberal V; Forrat R; Zhang C; Pan C; Bonaparte M; Yin W; Zheng L; Viscardi V; Wu Y; Ataman-Önal Y; Savarino S; Chen C
Microbiol Spectr; 2022 Jun; 10(3):e0071121. PubMed ID: 35604130
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
5. Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
Dayan GH; Langevin E; Forrat R; Zambrano B; Noriega F; Frago C; Bouckenooghe A; Machabert T; Savarino S; DiazGranados CA
Vaccine; 2020 Sep; 38(41):6472-6477. PubMed ID: 32773243
[TBL] [Abstract][Full Text] [Related]
6. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.
Dayan GH; Langevin E; Gilbert PB; Wu Y; Moodie Z; Forrat R; Price B; Frago C; Bouckenooghe A; Cortes M; Noriega F; DiazGranados CA
Vaccine; 2020 Apr; 38(19):3531-3536. PubMed ID: 32204943
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
9. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
[TBL] [Abstract][Full Text] [Related]
10. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
11. CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals.
DiazGranados CA; Langevin E; Bonaparte M; Sridhar S; Machabert T; Dayan G; Forrat R; Savarino S
Clin Infect Dis; 2021 May; 72(10):1730-1737. PubMed ID: 32198515
[TBL] [Abstract][Full Text] [Related]
12. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.
Nascimento EJM; George JK; Velasco M; Bonaparte MI; Zheng L; DiazGranados CA; Marques ETA; Huleatt JW
J Virol Methods; 2018 Jul; 257():48-57. PubMed ID: 29567514
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
Coronel-Martinez DL; Park J; López-Medina E; Capeding MR; Bonfanti AAC; Montalbán MC; Ramírez I; Gonzales MLA; Zambrano B; Dayan G; Chen Z; Wang H; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2022 Jun; 22(6):901-911. PubMed ID: 35364022
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
16. Rapid diagnostic tests for determining dengue serostatus: a systematic review and key informant interviews.
Luo R; Fongwen N; Kelly-Cirino C; Harris E; Wilder-Smith A; Peeling RW
Clin Microbiol Infect; 2019 Jun; 25(6):659-666. PubMed ID: 30664935
[TBL] [Abstract][Full Text] [Related]
17. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
18. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
[TBL] [Abstract][Full Text] [Related]
19. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
